Chugai Pharmaceutical will acquire ordinary shares totaling JPY 4,360 million from the market between May 1 and the end of May 2026, in conjunction with the introduction of a trust-type stock compensation plan.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4519","jir_company_name":"Chugai Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-04-24","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4519-20260424-03.pdf","jir_short_summary":"Chugai Pharmaceutical will acquire ordinary shares totaling JPY 4,360 million from the market between May 1 and the end of May 2026, in conjunction with the introduction of a trust-type stock compensation plan.","jir_summary":"### Overview of the Introduction of the Trust-Type Stock Compensation Plan\nAt the Board of Directors meeting held on April 24, 2026, Chugai Pharmaceutical Co., Ltd. resolved the scale and timing of acquiring the Company's ordinary shares in connection with the trust-type stock compensation plan. This plan aims to provide incentives to directors, subsidiary directors, employees, and others. The trust agreement will be in effect from April 27, 2026, until the end of May 2030. Shares will be acquired from the market and voting rights will not be exercised.\n\n### Impact on Shareholders and Future Schedule\nThe total acquisition amount is JPY 1,860 million for the Director Compensation BIP Trust and JPY 2,500 million for the Stock Grant ESOP Trust, totaling JPY 4,360 million. Share acquisition is scheduled to be conducted between May 1 and the end of May 2026. Accordingly, these shares will be granted to directors and employees through the trust, with no impact on shareholders' voting rights. The plan has already been approved at the Annual General Meeting of Shareholders held on March 26, 2026.","jir_financial_highlights":"Trust Fund Amount (Director Compensation BIP Trust): JPY 1,860 million (Unknown)\nTrust Fund Amount (Stock Grant ESOP Trust): JPY 2,500 million (Unknown)\nShare Acquisition Period: 2026-05-01 to End of May 2026 (Unknown)","jir_category":"","jir_hashtags":"#ChugaiPharmaceutical, #ShareBuyback, #TrustTypeStockCompensationPlan","jir_key_figures":"Director Compensation BIP Trust Fund Amount: JPY 1,860 million (including subsidiary directors)\nStock Grant ESOP Trust Fund Amount: JPY 2,500 million (including subsidiary employees)\nShare Acquisition Period: 2026-05-01 to End of May 2026","jir_meta_title":"[Chugai Pharmaceutical] Share Acquisition of JPY 4,360 Million Related to Trust-Type Stock Compensation Plan\uff5cMay 2026","jir_meta_description":"Chugai Pharmaceutical will acquire ordinary shares totaling JPY 4,360 million from the market in May 2026 in conjunction with the introduction of the trust-type stock compensation plan, aiming to provide incentives to directors and employees.","jir_og_title":"[Chugai Pharmaceutical] Share Acquisition of JPY 4,360 Million Related to Trust-Type Stock Compensation Plan\uff5cMay 2026","jir_og_description":"Chugai Pharmaceutical will acquire shares valued at JPY 4,360 million in May 2026 under the trust-type stock compensation plan and grant them to directors and employees.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6836,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-42518","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n